

## **AMITRIPTYLINE:**

**Class:** Tricyclic antidepressant

**Indications:** Depression, Chronic pain management, Diabetic neuropathy, Migraine Prophylaxis, post-traumatic stress disorder (PTSD)

**Available dosage form in the hospital:** TAB (10MG, 25MG, 50MG)

**Trade Names:**

**Dosage:**

**Depression:** Oral: 50-150 mg/day single dose at bedtime or in divided doses; dose may be gradually increased up to 300 mg/day.

**Chronic pain management (unlabeled use):** Oral: Initial: 25 mg at bedtime; may increase as tolerated to 100 mg/day.

**Diabetic neuropathy (unlabeled use):** Oral: 25-100 mg/day (Bril, 2011)

**Migraine prophylaxis (unlabeled use):** Oral: Initial: 10-25 mg at bedtime; usual dose: 150 mg; reported dosing ranges: 10-400 mg/day

**Post-traumatic stress disorder (PTSD) (unlabeled use):** Oral: 75-200 mg/day

**Geriatric:** Depression: Oral: Initial: 10-25 mg at bedtime; dose should be increased in 10-25 mg increments every week if tolerated; dose range: 25-150 mg/day. See Renal/Hepatic Impairment.

### **Renal Impairment:**

Nondialyzable

### **Hepatic Impairment:**

Use with caution and monitor plasma levels and patient response

### **Common side effect:**

**Cardiovascular:** Orthostatic hypotension, tachycardia, ECG changes (nonspecific), AV conduction changes, MI, stroke, heart block, arrhythmia, syncope, hypertension, palpitation

**Central nervous system:** Restlessness, dizziness, insomnia, sedation, fatigue, anxiety, cognitive function impaired, seizure, extrapyramidal symptoms, coma, hallucinations, confusion, disorientation, coordination impaired, ataxia, headache, nightmares, hyperpyrexia

**Dermatologic:** Allergic rash, urticaria, photosensitivity, alopecia

**Endocrine & metabolic:** Syndrome of inappropriate ADH secretion

**Gastrointestinal:** Weight gain, xerostomia, constipation, paralytic ileus, nausea, vomiting, anorexia, stomatitis, peculiar taste, diarrhea, black tongue

**Genitourinary:** Urinary retention

**Hematologic:** Bone marrow depression, purpura, eosinophilia

**Neuromuscular & skeletal:** Numbness, paresthesia, peripheral neuropathy, tremor, weakness

**Ocular:** Blurred vision, mydriasis, ocular pressure increased

**Miscellaneous:** Diaphoresis, withdrawal reactions (nausea, headache, , malaise)

**Pregnancy Risk Factor:** C